330 related articles for article (PubMed ID: 24659882)
1. Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases.
Upadya MH; Aweya JJ; Tan YJ
World J Gastroenterol; 2014 Mar; 20(11):2913-26. PubMed ID: 24659882
[TBL] [Abstract][Full Text] [Related]
2. DEAD-box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs.
Kukhanova MK; Karpenko IL; Ivanov AV
Molecules; 2020 Feb; 25(4):. PubMed ID: 32102413
[TBL] [Abstract][Full Text] [Related]
3. Cellular DEAD-box RNA helicase DDX6 modulates interaction of miR-122 with the 5' untranslated region of hepatitis C virus RNA.
Biegel JM; Henderson E; Cox EM; Bonenfant G; Netzband R; Kahn S; Eager R; Pager CT
Virology; 2017 Jul; 507():231-241. PubMed ID: 28456022
[TBL] [Abstract][Full Text] [Related]
4. DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication.
Ariumi Y; Kuroki M; Abe K; Dansako H; Ikeda M; Wakita T; Kato N
J Virol; 2007 Dec; 81(24):13922-6. PubMed ID: 17855521
[TBL] [Abstract][Full Text] [Related]
5. DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control.
Chang PC; Chi CW; Chau GY; Li FY; Tsai YH; Wu JC; Wu Lee YH
Oncogene; 2006 Mar; 25(14):1991-2003. PubMed ID: 16301996
[TBL] [Abstract][Full Text] [Related]
6. Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein.
Angus AG; Dalrymple D; Boulant S; McGivern DR; Clayton RF; Scott MJ; Adair R; Graham S; Owsianka AM; Targett-Adams P; Li K; Wakita T; McLauchlan J; Lemon SM; Patel AH
J Gen Virol; 2010 Jan; 91(Pt 1):122-32. PubMed ID: 19793905
[TBL] [Abstract][Full Text] [Related]
7. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
Suzuki T
Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
[TBL] [Abstract][Full Text] [Related]
8. High-throughput approaches to unravel hepatitis C virus-host interactions.
Colpitts CC; El-Saghire H; Pochet N; Schuster C; Baumert TF
Virus Res; 2016 Jun; 218():18-24. PubMed ID: 26410623
[TBL] [Abstract][Full Text] [Related]
9. The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses.
Shin EC; Han JW; Kang W; Kato T; Kim SJ; Zhong J; Kim S; Park SH; Sung PS; Watashi K; Park JY; Windisch MP; Oh JW; Wakita T; Han KH; Jang SK
Viruses; 2020 Mar; 12(3):. PubMed ID: 32168867
[No Abstract] [Full Text] [Related]
10. Pathogen-Associated Molecular Pattern Recognition of Hepatitis C Virus Transmitted/Founder Variants by RIG-I Is Dependent on U-Core Length.
Kell A; Stoddard M; Li H; Marcotrigiano J; Shaw GM; Gale M
J Virol; 2015 Nov; 89(21):11056-68. PubMed ID: 26311867
[TBL] [Abstract][Full Text] [Related]
11. DDX6 (Rck/p54) is required for efficient hepatitis C virus replication but not for internal ribosome entry site-directed translation.
Jangra RK; Yi M; Lemon SM
J Virol; 2010 Jul; 84(13):6810-24. PubMed ID: 20392846
[TBL] [Abstract][Full Text] [Related]
12. DDX3 DEAD-box RNA helicase is a host factor that restricts hepatitis B virus replication at the transcriptional level.
Ko C; Lee S; Windisch MP; Ryu WS
J Virol; 2014 Dec; 88(23):13689-98. PubMed ID: 25231298
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.
Perez S; Kaspi A; Domovitz T; Davidovich A; Lavi-Itzkovitz A; Meirson T; Alison Holmes J; Dai CY; Huang CF; Chung RT; Nimer A; El-Osta A; Yaari G; Stemmer SM; Yu ML; Haviv I; Gal-Tanamy M
PLoS Genet; 2019 Jun; 15(6):e1008181. PubMed ID: 31216276
[TBL] [Abstract][Full Text] [Related]
14. Role reversal of functional identity in host factors: Dissecting features affecting pro-viral versus antiviral functions of cellular DEAD-box helicases in tombusvirus replication.
Wu CY; Nagy PD
PLoS Pathog; 2020 Oct; 16(10):e1008990. PubMed ID: 33035275
[TBL] [Abstract][Full Text] [Related]
15. Can tobacco use promote HCV-induced miR-122 hijacking and hepatocarcinogenesis?
Zhao L; Li F; Taylor EW
Med Hypotheses; 2013 Feb; 80(2):131-3. PubMed ID: 23218444
[TBL] [Abstract][Full Text] [Related]
16. DDX60L Is an Interferon-Stimulated Gene Product Restricting Hepatitis C Virus Replication in Cell Culture.
Grünvogel O; Esser-Nobis K; Reustle A; Schult P; Müller B; Metz P; Trippler M; Windisch MP; Frese M; Binder M; Fackler O; Bartenschlager R; Ruggieri A; Lohmann V
J Virol; 2015 Oct; 89(20):10548-68. PubMed ID: 26269178
[TBL] [Abstract][Full Text] [Related]
17. Studying the Hepatitis C Virus-Induced Epigenetic Signature After Cure with Direct-Acting Antivirals.
Perez S; Gal-Tanamy M
Methods Mol Biol; 2019; 1911():191-207. PubMed ID: 30593627
[TBL] [Abstract][Full Text] [Related]
18. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
[TBL] [Abstract][Full Text] [Related]
19. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
Kurokawa K; Ohki T; Kato J; Fukumura Y; Imai M; Shibata C; Arai J; Kondo M; Takagi K; Kojima K; Seki M; Mori M; Toda N; Tagawa K
J Med Case Rep; 2020 May; 14(1):62. PubMed ID: 32456712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
